impacting lung cancer survivorship
CONTENTS

Letter from President and Chairman of the Board . . . 2
Our Values .................................................. 3
Research Investment ........................................ 4-10
Scientific Advisory Board ............................... 11
Building Informed, Empowered Communities ........ 12-13
Raising Awareness Through Events ................... 14-15
Donors ......................................................... 16-25
Financial Highlights ...................................... 26-27
How to Get Involved ...................................... 28
Leadership ............................................. inside back cover
...through strategic investments in research

Our Vision  A world where no one dies of lung cancer.

Our Mission  LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as providing community, support and education for all those affected by the disease.

Our Motivation
• The 1 in 14 men and women who will be diagnosed with lung cancer in their lifetime.
• The 228,000 people who will be diagnosed with lung cancer this year.
• The almost 400,000 people living with the disease in the United States today.
• The 1.8 million mothers, fathers, brothers, sisters, daughters, sons, and friends who have died of lung cancer since LUNGevity was founded in 2001.
Dear Friends,

LUNGevity continues to support the lung cancer community—and be supported by it—in a powerful collaboration that will lead to a time when thriving long-term lung cancer survivorship will be the norm.

In 2013, we persisted in our quest to improve lung cancer mortality rates by funding even more innovative, impactful science. Last year’s inaugural mentored Career Development Awards yielded excellent progress in the young awardees’ research itself, as well as in their development toward becoming independent researchers, and three new awardees were added to the program this year. Highly promising projects in both our Early Detection Award and Targeted Therapeutics Award programs were also funded. Their goals range from early detection of both non-small cell AND small cell lung cancers to making radiotherapy more effective, targeting KRAS mutations, and overcoming resistance to EGFR inhibitors.

With these, LUNGevity has reached the milestone of having funded 100 projects at 56 institutions in 23 states since our inception. Each of these projects has contributed to the body of knowledge necessary to successfully challenge this very complex disease.

We are also proud this year to have added to the many other services we offer to the lung cancer community by launching the Survivor Resource Center, dedicated to providing help with the issues—practical, physical, and emotional—that survivors encounter from diagnosis forward. The Survivor Resource Center complements our unique Caregiver Resource Center, which offers assistance to those who devote their time and energy to care for a loved one battling lung cancer.

More than 120 participants from across the country joined us at our third annual HOPE Summit in May for a weekend of fellowship and education; all left inspired by each other’s stories of strength and hope. LUNGevity also sponsored more than 80 grassroots events and galas in 2012, events that brought together those touched by lung cancer to celebrate and memorialize.

We couldn’t do any of this without you, our event participants and volunteers, our corporate sponsors, and our donors. Your contributions allow us to continue our essential work. We thank you for your support. Our promise to you is that these donations will always be used in the most thoughtful way possible and that our work will not stop until we have stopped lung cancer.

Sincerely,

Andrea Ferris
President and Chairman
We believe it’s important for our board, our staff, and our constituents to know the values that drive all our actions.

We are:

**Focused on Survivorship**
- 100% dedicated to increasing and improving lung cancer survivorship

**Results-oriented**
- Always challenging the status quo and seeking a more efficient and effective way
- Rigorously measuring our performance to ensure maximum impact

**Compassionate and Respectful**
- Building and sustaining a community for all those affected by lung cancer
- Respectful of all people with lung cancer, caregivers, loved ones, medical professionals, donors, board members, and employees

**Collaborative**
- Committed to being good partners and strategic collaborators to enable us to reach our goal more quickly and efficiently, including through our scientific endeavors

**Transparent**
- Fiscally responsible and holding ourselves to the highest ethical standards
Need for Funding Investments in research for early detection and better treatments in other major cancers have resulted in marked increases in survival among those affected by the diseases. In the meantime, lung cancer survival rates have remained low, on par with the relatively low level of federal funding.

Five-year survival rates for all other major cancers have increased significantly from their already higher rates. Lung cancer five-year survival is still only 17%.

In 2012, the federal government funding for research into lung cancer has remained a fraction of that for other major cancers.

Federal Research Funding by Type of Cancer (dollars per life lost)

Lung Cancer Alliance 2012 Lung Cancer Facts
Translational Research into Early Detection and Targeted Therapies Program

It’s widely agreed that many promising ideas are losing their momentum after the Basic Research phase, long before the patient can see any benefit in the clinic. Yet with increasing risk in the research environment and the economy, industry and venture capital have been even more reluctant to step in before the Clinical Development phase. That ever-widening gap in research funding between the basic research phase and the clinical phase has become known as the “Valley of Death” because so many exciting observations and insights get lost here.

LUNGevity’s Translational Research Program facilitates the transition of projects from the laboratory to the clinic. Scientists and clinicians seek to apply fundamental knowledge of lung cancer and bring the benefits of the new understandings to patients more quickly and efficiently through a seamless collaboration leading to more effective detection, diagnosis or treatment of lung cancer.

We have a great opportunity in lung cancer radiation oncology to improve outcomes. The majority of patients present with disease that is too advanced for surgery alone. I lost my father to lung cancer, even though his was found when it was only locally advanced. I believe we can overcome those limitations that keep us from saving people like him and others in the near future.

DAVID KOZONO, MD, PhD
2013-2016 LUNGevity Career Development Awardee
Recipient of LUNGevity Foundation’s 2013 Melissa Lumberg Zagon Founders’ Award
Dana-Farber Cancer Institute
LUNGevity’s Scientific Research Program is focused on finding a better way to detect and treat lung cancers and prevent their recurrence. Funds are invested in translational research — the process of applying knowledge generated through basic discovery research to the treatment and prevention of human disease, taking science “from the bench to the bedside.”

Specifically, investments are made in:
- Widely available, noninvasive, cost-effective diagnostic tools
- Therapies targeted at specific biological pathways
- Applying understanding and differentiation of the biology of the tumor to prevent recurrence of the cancer

Since its founding in 2001, LUNGevity has funded 100 research projects at 56 institutions in 23 states, focusing on early detection as well as more effective treatments of lung cancer.

MAP KEY
- States with LUNGevity-funded Research
★ - States with Scientific Advisory Board Members
Targeting the c-MET gene in lung cancer

In 2004, while at the University of Chicago Pritzker School of Medicine, Dr. Patrick Ma received a joint grant from LUNGevity Foundation and the American Cancer Society to study c-MET, then a relatively unknown gene in lung cancer. His research contributed to the groundbreaking discovery that mutations in c-MET in lung cancer trigger tumor growth and formation of new blood vessels that supply the tumor with nutrients. His research also contributed to the understanding of the role of c-MET overexpression in lung cancer. Increased amounts of c-MET are linked to poor outcomes and low survival in lung cancer. Dr. Ma’s research shows that it is possible to block c-MET gene function with specific drugs as novel targeted lung cancer therapy. A large number of these c-MET targeting drugs are now being tested in lung cancer patients, and two of them, tivantinib and onartuzumab, have progressed into the final stages of clinical testing. If these drugs succeed in this final stage of testing, c-MET blockers will add to the arsenal of drugs to fight lung cancer.

Now Director of the Aerodigestive Oncology Translational Research Program in the Department of Translational Hematology and Oncology Research at Cleveland Clinic Taussig Cancer Institute, Dr. Ma continues to research lung cancer treatments. Dr. Ma’s recent research points to different c-MET mutation profiles across racial groups. Dr. Ma hopes to expand on these findings and investigate the c-MET gene alterations and genomic biomarkers of c-MET targeting therapeutic response across larger populations, thereby enabling even more personalized treatment of lung cancer.

IDO inhibitors help the immune system tackle cancer cells

The immune system is the body’s defense mechanism for detecting and eliminating infections as well as newly-formed cancer cells. Tumors often suppress the immune response in cancer patients. Dr. George Prendergast, President and CEO of The Lankenau Institute for Medical Research, focuses his own research on understanding how and why tumors suppress the body’s own immune defense system. He found that tumors make an enzyme called IDO that enables the tumor cells to escape from the immune surveillance system. LUNGevity funding helped propel Dr. Prendergast’s research to discover that an IDO inhibitor called D-1MT reduces lung tumors in animals. IDO inhibitors, which recently entered phase II clinical trials for cancer treatment in patients, have been named among the “top 10” experimental treatments that could cure cancer by the National Cancer Institute.

The first year after I was diagnosed with stage IV non-small cell lung cancer was very lonely. It was such a relief to meet others like me at LUNGevity’s 2012 HOPE Summit. I am ALK positive, and targeted therapies have already been developed for my kind of lung cancer. I want personalized treatments to be found for all kinds of lung cancer, so that more people will survive this disease.

HEIDI HENN
Diagnosed 2012
Early Detection  Finding lung cancer earlier translates to more survivors. Yet, currently, most lung cancers are found after the cancer has metastasized, making it much more difficult to treat.

The National Lung Screening Trial proved a significant reduction in mortality when lung cancer was found at earlier stages using low-dose computed tomography (LDCT). But the high false positive rate of LDCT results in extensive additional testing or other procedures. The only lung cancer nonprofit with a focus on early detection research, LUNGevity funds support the development of blood- or sputum-based biomarkers to complement LDCT. Our goal is to reverse the numbers, so that the majority of lung cancers are found in the curable earlier stages.

2013 EARLY DETECTION RESEARCH AWARDS

The Early Detection Awards for Translational Research Program supports new approaches to improve clinical methods for the detection and diagnosis of primary tumors.

Feng Jiang, MD, PhD  
*University of Maryland, Baltimore*

Sanford A. Stass, MD  
*University of Maryland School of Medicine and Medical Center*

**Sputum biomarkers for the early detection of lung cancer**

Awarded with support from Upstage Lung Cancer

Dr. Jiang is identifying sputum biomarkers that could improve the process of detecting lung cancer in its earliest stages. Major health organizations are now starting to recommend low-dose computed tomography (LDCT) scans for people at high risk for lung cancer. However, because of LDCT’s high false positive rate, many patients could be diagnosed with lung cancer but not actually have the disease. To help eliminate the physical, emotional and financial costs associated with a false lung cancer diagnosis, Dr. Jiang is working to identify highly effective biomarkers in sputum. These biomarkers will lay the groundwork for developing a non-invasive test that complements LDCT scans and improves the accuracy of diagnosing early stage lung cancer.

Ignacio Wistuba, MD  
and  
Humam Kadara, PhD  
*University of Texas MD Anderson Cancer Center*

**Identification of biomarkers for the detection of small cell lung cancer**

Drs. Wistuba and Kadara are identifying biomarkers that could ultimately lead to the first test to detect small cell lung cancer in its earliest and most treatable stages. They are using cutting-edge technologies to compare the molecular characteristics of cells lining the nasal passages and airways of small cell lung cancer patients with those of patients who have benign disease or other lung cancer types. Their goal is to identify the most promising biomarkers for identifying small cell lung cancer and then to test whether these biomarkers can be used to accurately diagnose patients with small cell lung cancer.
**Targeted Therapeutics**  There has been an exciting increase in understanding of the cellular drivers of lung cancer in the past several years. This understanding is being driven in part by breakthroughs in technology like next-generation sequencing. In non-small cell lung cancer (NSCLC), for instance, driver mutations that are druggable targets have been identified in more than half of all cases. New classes of drugs, like immunotherapies, are also showing great promise. Matching therapies with the right patient for maximum effectiveness and minimum side effects remains a challenge, as does overcoming resistance. LUNGevity wants to ensure that every patient has the best treatment match for their particular lung cancer, resulting in longer, better-quality lives.

**2013 THERAPEUTICS RESEARCH AWARDS**
LUNGevity's Targeted Therapeutics Research program supports the discovery and validation of biomarkers or novel targeted therapeutics that will make a difference in the clinical treatment and survival of patients.

**Balazs Halmos, MD, and Simon Cheng, MD, PhD**  
*Columbia University Medical Center*

**Haiying Cheng, MD, PhD**  
*Albert Einstein College of Medicine*

Identification of predictive biomarkers of chemoradiotherapy in lung cancer

Drs. Halmos, Cheng, and Cheng are working on a way to increase the effectiveness of radiation and chemotherapy that could lead to personalized NSCLC treatments. In previous studies, they found that the results of treating NSCLC with the most commonly used chemotherapy drug, cisplatin, could be improved by combining it with another drug, a DNA repair inhibitor, that blocks the way cancer cells can repair damage caused by cisplatin. Continuing this work, they are testing two follow-on hypotheses: 1) whether DNA repair inhibitors will also help chemotherapy and radiation work better in combination and 2) whether tumor cells with inherently reduced activity in these DNA repair mechanisms are more responsive to chemoradiation treatment, and whether that responsiveness can be predicted through biomarkers that indicate selected resistance.

**Lecia V. Sequist, MD, and Jeffrey Engelman, MD, PhD**  
*Massachusetts General Hospital*

**Joel Neal, MD, PhD**  
*Stanford University Medical Center*

**Determining mechanisms of resistance to next-generation EGFR inhibitors**
Dr. Sequist and her colleagues are determined to help NSCLC patients whose cancers become resistant to targeted therapies after a period of responsiveness. Building on previous work in understanding how tumors become resistant to a particular type of drug called EGFR inhibitors, they will be using next-generation deep sequencing technology and an established repeat biopsy program to study resistance to the new class of EGFR inhibitors. Working in real-time between the clinic and the lab, this program will help the team to develop models that explain how NSCLC patients can acquire drug resistance to targeted therapies, in turn directing individual patients to the most appropriate treatment strategy to overcome resistance.

**Frank J. Slack, PhD, and Joanne Weidhaas, MD, PhD**  
*Yale University*

**Hai Tran, PharmD**  
*University of Texas MD Anderson Cancer Center*

**Targeting KRAS mutations in lung cancer**
Dr. Slack and his colleagues have discovered a set of inherited genetic variations that could potentially be used as biomarkers for personalized lung cancer treatments. One of these genetic variations, called the “KRAS-variant,” is found in about 20 percent of NSCLC patients and has been shown to be linked to an increased risk of NSCLC. Building on exciting preliminary data, they will focus on studying the KRAS-variant as a biomarker for disease and as a new target for developing personalized treatment options for NSCLC patients.
Career Development Awards for Translational Research  LUNGevity’s Career Development Awards Program has the dual goals of advancing our knowledge of lung cancer while retaining, and advancing the careers of, talented future research leaders who will keep the field of lung cancer research vibrant with new ideas. Awardees participate in a structured mentoring program at their institutions and become ex officio members of LUNGevity’s Scientific Advisory Board for the duration of the award. Their funded projects are focused on the early detection of lung cancer and/or personalized treatment. Grants are for $100,000 per year with a possible three-year commitment for a maximum of $300,000.

2013-2016 Career Development Awardees

Timothy Burns, MD, PhD
University of Pittsburgh Cancer Institute
Targeting KRAS-mutant NSCLC through inhibition of mTOR and Hsp90
Dr. Burns is working on targeted therapies for non-small cell lung cancer patients with mutations in a gene called KRAS. Previous work showed that the drug ganetespib can cause these tumors to shrink. Dr. Burns is working to understand the causes of the drug resistance that often follows, in order to identify new treatment strategies. He has found a combination of medicines that may overcome this resistance, and is now identifying biomarkers that will predict a patient’s response to treatment. Dr. Burns will conduct a clinical trial to test this new treatment and confirm that these biomarkers will reliably identify patients who are most likely to benefit from this treatment option.

David Kozono, MD, PhD
Dana-Farber Cancer Institute
Biomarkers for NSCLC radiosensitization by proteasome inhibition
(Recipient of LUNGevity Foundation’s 2013 Melissa Lumberg Zagon Founders’ Award)
Dr. Kozono is working to improve lung cancer survival rates by developing radiation treatments that selectively kill cancer cells while leaving the surrounding vital organs unharmed. In previous work, he found that inhibiting the function of the proteasome, the cell’s recycling bin for proteins, caused tumor cells in mice to be more responsive to radiation treatment. Because the drug bortezomib inhibits proteasome function and is already FDA-approved for the treatment of multiple myeloma, Dr. Kozono is studying the effects of combining bortezomib with radiation therapy as a possible treatment for lung cancer.

Meredith Tennis, PhD
University of Colorado Denver
Biomarkers for targeted lung cancer chemoprevention
Dr. Tennis is studying two drugs, iloprost and pioglitazone, that have demonstrated promise in reducing NSCLC risk. Iloprost was shown to reduce the damage from smoking cigarettes, and pioglitazone was associated with decreased lung cancer risk in diabetic patients. Because these drugs are not effective in every patient, invasive biopsies may be required during clinical trials to determine if these treatments are working. Dr. Tennis aims to identify biomarkers that signal that these drugs are working in order to replace these invasive procedures with simpler tests. Dr. Tennis is also working to find other biomarkers that will indicate if a patient is likely to benefit from these drugs.

2012-2015 Career Development Awardees

Jennifer Beane, PhD
Boston University
Biomarkers of pre-malignant disease progression for lung cancer detection

Lauren A. Byers, MD
University of Texas MD Anderson Cancer Center
PARP1 as a novel therapeutic target in small cell lung cancer

Mohamed Hassanein, PhD
Vanderbilt University Medical Center
Developing new non-invasive methods for the diagnosis of lung cancer

Christopher A. Maher, PhD
Washington University in St. Louis
Molecular predictors of outcome in non-small cell lung cancer

Viswam S. Nair, MD
Stanford University
In-vivo and in-vitro diagnostics to improve lung cancer care
Scientific Advisory Board  LUNGevity invests funds with the support of a world-class Scientific Advisory Board composed of leaders in their respective fields. This board meets twice a year to discuss research strategy, share new scientific developments, oversee ongoing funded projects, and review grant proposals. These leaders in fields such as proteomics, biostatistics, immunotherapy, and others are instrumental in improving the mortality rates of lung cancer patients. With their broad range of expertise, Scientific Advisory Board members guide the strategy of LUNGevity’s funding of research into early detection techniques—from tissue-based (blood, saliva, sputum) tests to imaging procedures—as well as into more effective therapies in order to develop the most promising protocols for increasing lung cancer survival rates.

Denise R. Aberle, MD  
David Geffen School of Medicine at UCLA  
Professor and Vice Chair of Research, Radiology

Nasser K. Altorki, MB, BCh  
NewYork-Presbyterian/Weill Cornell Medical Center  
Professor of Cardiothoracic Surgery  
Chief, Division of Thoracic Surgery

Philip D. Bonomi, MD  
Rush University Medical Center  
Alice Pirie Wirtz Professor of Medical Oncology  
Director, Division of Hematology-Oncology

David P. Carbone, MD, PhD  
The Ohio State University  
Professor, Division of Medical Oncology  
Barbara J. Bonner Chair in Lung Cancer Research  
Director of the Thoracic Oncology Center

Martin “Mac” Cheever, MD  
Cancer Immunotherapy Trials Network  
Principal Investigator

Fred Hutchinson Cancer Research Center  
Member & Director of Solid Tumor Research

University of Washington  
Professor of Medicine/Oncology

Steven M. Dubinett, MD  
David Geffen School of Medicine at UCLA  
Chief, Division of Pulmonary and Critical Care Medicine  
Senior Associate Dean for Translational Research  
Associate Vice Chancellor for Research  
Director, Clinical and Translational Science Institute (CTSI)

John Heymach, MD, PhD  
University of Texas MD Anderson Cancer Center  
Professor and Chairman, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine

James R. Jett, MD  
National Jewish Health  
Professor of Medicine

Robert L. Keith, MD  
University of Colorado Denver  
Professor of Medicine and Cancer Biology  
Denver VAMC  
Associate Chief of Staff—Research

J. Jack Lee, PhD, DDS  
University of Texas MD Anderson Cancer Center  
Professor of Biostatistics  
Kenedy Foundation Chair in Cancer Research

Scott M. Lippman, MD  
University of California, San Diego  
Director, Moores Cancer Center  
Chugai Pharmaceutical Chair  
Professor of Medicine

Pierre P. Massion, MD  
Vanderbilt University Medical Center  
Professor of Medicine  
Ingram Professor of Cancer Research  
Professor of Cancer Biology  
Director, Thoracic Program at the Vanderbilt-Ingram Cancer Center

Charles M. Rudin, MD, PhD  
Memorial Sloan-Kettering Cancer Center  
Chief of the Thoracic Oncology Service

Lawrence H. Schwartz, PhD  
Columbia University Medical Center  
James Picker Professor and Chairman, Department of Radiology  
NewYork-Presbyterian/  
Columbia University Medical Center  
Radiologist-in-Chief

Lecia V. Sequist, MD, MPH  
Harvard Medical School  
Associate Professor of Medicine  
Massachusetts General Hospital Cancer Center—Center for Thoracic Cancer  
Attending Oncologist

Steven J. Skates, PhD  
Harvard Medical School and  
Massachusetts General Hospital  
Associate Professor

Avrum E. Spira, MD, MSci  
Boston University  
Professor of Medicine, Pathology and Bioinformatics  
Alexander Graham Bell Professor in Healthcare Entrepreneurship  
Chief, Section of Computational Biomedicine

Margaret R. Spitz, MD, MPH  
Baylor College of Medicine  
Professor, Dan L. Duncan Cancer Center
The past year saw several major milestones in LUNGevity’s support for all people affected by lung cancer.

- **Over 80 survivors attended the national HOPE Summit** in May, Lung Cancer Hope Month—doubling the 2012 survivor attendance. Along with caregivers, speakers and other advocates, this brought the total to 120 participants. Designed for people living with lung cancer at all stages of the disease, the HOPE Summit featured educational sessions, inspirational speakers, media opportunities, and the all-important opportunity to connect with others diagnosed with lung cancer. The 2013 Summit offered two program tracks for the first time, to address the needs of people at various points from diagnosis.

- **A new short-video series** was launched as part of Ask the Experts, leading to increased access and viewership of topics across lung cancer, and new webinars included “Advances in Surgery for Lung Cancer” and “Molecular Signatures to Assess Prognosis in Early Stage Lung Cancer.”

- **LifeLine Support Partners**, our free personalized service that matches a lung cancer patient or caregiver to a peer, continues to grow. We create matches for our referral partners at major institutions and organizations across the country.

- **LUNGevity entered into an agreement with Meals to Heal** to provide monthly blogs written by oncology nutrition specialists on the nutritional issues affecting those in treatment for lung cancer and on the benefits of good nutrition for those living with lung cancer.

- **The online Survivor Resource Center** was launched in January, complementing the Caregiver Resource Center launched the previous year.

---

**I am grateful to LUNGevity for the funding they provide, which contributes to the development of targeted therapies like the drug that put my cancer into remission. Now I want to help people who are newly diagnosed to see that there are people who are surviving.**

**MATT ELLEFSON**
Lungenevity advocate and LifeLine Support Partner
Diagnosed in 2009 with advanced non-small cell lung cancer
LUNGevity’s 2013 HOPE Summit

1) Andrea Ferris, President and Chairman of LUNGevity Foundation opened the HOPE Summit with words of inspiration and thanks to our valued sponsors.

2) Participants shared their answers to “What gives you Hope?”

3) Survivor and Nashville-based singer-songwriter Martha McCann Lesnick performed a beautiful song she wrote called “Breathe Hope.”

4) Participants share a moment of friendship and support.

5) An evening of sightseeing in our nation’s capital allowed for more relaxed bonding.

6) Survivors Jorge Gonzalez and Barbara Jones with her sister Shirley Harris all reunited after meeting at the 2012 HOPE Summit, and posed together for a celebratory portrait.

7) Survivor Heather Geraghty and advocate/author and speaker Dr. Lynne Eldridge.

8) Survivor Lynn Shih and her husband traveled from Washington State to participate in the Summit.

9) Survivors Darrell (Doc) Rodgers and Anne Gallagher on a panel about “Managing Your Care and Medical Team.”

10) Dr. Emil Abramian of Cancer Treatment Centers of America spoke about “Pulmonary Rehabilitation.”
LUNGevity’s 2013 events nationwide raised over $4 million.

1) Survivors, identifiable in their green Breathe Deep t-shirts, gathered onstage in Dallas-Fort Worth. 2) Participants gathered before the start of the Breathe Deep North Shore, IL, 5K fun run/2K walk. 3) LUNGevity distributes information about their free support and education services for anyone affected by lung cancer, and the startling facts about lung cancer. 4) Our first-ever “Breathe Deep and Jump” signature rappelling event, down the Woodward and Lothrop Building in downtown DC. 5) Our golf tournaments are a popular choice, combining a passion for golf with raising valuable funds. 6) LUNGevity blue dominated the color palette as participants kicked off this Breathe Deep run/walk. 7) Our Galas have been a success thanks to the help of our dedicated event chairs. 8) Friends and family members who are no longer able to walk along are remembered and memorialized along the path at the events. 9) All events share the Breathe Deep identity for signage, t-shirts and other supporting materials, maximizing the brand impact across the country and creating a visual virtual community.
Events coast-to-coast! We are grateful to all of our participants and supporters. These 80+ events share the common goals of increasing awareness of the urgent need for earlier detection and improved treatment of lung cancer and raising critical funds for research to change the outcomes. More than 25,000 people participated in LUNGevity events, raising invaluable awareness and over $4 million.

LUNGevity Grassroots, Benefactor and Internal Events July 1, 2012-June 30, 2013

**Arizona**
- Breathe Deep Phoenix

**California**
- Breathe Deep Bay Area
- Breathe Deep San Diego
- Paddle for Humanity, Lake Tahoe

**Connecticut**
- Breathe Deep Westport

**Delaware**
- Skim to Breathe, Northside

**District of Columbia**
- Breathe Deep and Jump
- Breathe Deep DC
- Hill Country Happy Hour
- LUNGevity’s Musical Celebration of Hope Gala
- Paddle for Humanity
- Team Labrecque-LUNGevity—Run as One Marine Corps Marathon

**Florida**
- Breathe Deep Pompano Beach
- Paddle for Humanity, Deerfield Beach

**Georgia**
- Breathe Deep Atlanta
- Breathe Deep Blue Ridge

**Illinois**
- Breathe Deep Busse Woods
- Breathe Deep Central Illinois
- Breathe Deep Kankakee
- Breathe Deep Lake Arlington
- Breathe Deep Lena
- Breathe Deep Naperville
- Breathe Deep North Shore
- Breathe Deep Yogathon, Highland Park
- 6th Annual Pauline Moraco-Arredondo Lung Cancer Walk and Rally, Chicago
- Annual LUNGevity Foundation Golf Outing—Royal Melbourne Country Club, Long Grove
- Deerfield High School Annual School Chest
- Dress Down Chicago
- Jannie’s Hope Charity Golf Outing, Naperville
- John Whiteside/Beatrice Green Lung Cancer Walk, Arlington Heights

**Iowa**
- Breathe Deep Des Moines

**Maryland**
- Breathe Deep 3-Day Walk, Bethesda and Nationwide
- Breathe Deep Baltimore
- Breathe Deep Columbia
- Bloomingdale’s Private Evening of Shopping with Special Savings, Chevy Chase
- J. McLaughlin Shopping Event, Bethesda
- Suzi Carmassi Golf Classic, Ijamsville

**Massachusetts**
- Breathe Deep Boston
- Paddlepaloza, Newton
- Small Army for a Cause, Boston
- Upstate Lung Cancer’s 4th Annual Cabaret Concert, “Unforgettable,” Boston
- Hoops for Heart and Hoops for Hope, Wrentham

**Michigan**
- Breathe Deep Ann Arbor
- Breathe Deep Michigan, Birmingham
- Jeans for Charity, Southfield

**Minnesota**
- A Breath of Hope Lung Foundation 6th Annual Twin Cities Lung Walk/Run
- Paddle for Humanity, Minneapolis

**Missouri**
- The Lung Hill Run, Kansas City

**Nationwide**
- Seashells & Balloons: Lisa Shapiro Memorial Tournament

**New Hampshire**
- Breathe Deep New Hampshire, Concord

**New Jersey**
- 2nd Annual Lung Cancer Fundraiser, Maple Shade
- Every Breath Counts: Walk, Run, Survive, Ocean City
- The Heather Saler 9th Annual Lung Cancer Walk, Pennsauken

**New York**
- Breathe Deep CNY, Liverpool
- Breathe Deep NYC
- James Lucca Memorial Golf Event, Schenectady
- Labrecque-LUNGevity Ping Pong at SPIN NYC
- Team Labrecque-LUNGevity—NYC Half Marathon
- Team Labrecque-LUNGevity—Run as One, New York City
- Team Labrecque-LUNGevity—Run as One ING New York Marathon
- Tom Zangas Lung Cancer Foundation 5th Annual 5k Run/Walk

**North Carolina**
- Breathe Deep Cary
- Breathe Deep Wilmington

**Ohio**
- Breathe Deep Columbus
- Breathe Deep Newark

**Pennsylvania**
- Breathe Deep NE Pennsylvania, Kingston
- Breathe Deep Philadelphia
- Chris Gemmell Memorial Open: 5th Annual Golf Tournament and Dinner, Gettysburg
- Manayunk Tomato Trot, Philadelphia
- Shakin’ It Up, Pittsburgh

**Tennessee**
- Breathe Deep Nashville
- Breathe In the Season, Nashville

**Texas**
- Breathe Deep DFW
- 2nd Annual Golf Tournament in Memory of Frances Blackwell, Austin
- Paddle for Humanity, Austin

**Utah**
- Breathe Deep Salt Lake City

**Virginia**
- Breathe Deep DC Golf Classic, Arlington
- Breathe Deep Haymarket
- 5th Annual Beth Whiteacre Golf Tournament, Lorton
- GRAFF Diamond Trunk Show at Saks Fifth Avenue, Tysons Corner

**Washington**
- Breathe Deep Seattle
- Breathe Deep Seattle: An Evening in Honor of Lung Cancer Awareness Month
Donors* The generous support from our friends allows LUNGevity to fund cutting-edge translational research and to offer information, support and, most importantly, hope to lung cancer survivors and their families.

BEACONS OF HOPE
Individual, Corporate and Organizational Gifts of $5000 and above
Anne Boyd Lichtenstein Foundation
Arnold & Porter LLP
Astellas Pharma US, Inc.
Jean Baderschneider and Pat MacArevey
Bajaj Family Foundation LLC
Pam and Steve Barger
Grace and Morton Bender
Karen and Chris Donatelli
Deerfield High School 2012
Dance Connection Parent

Corporate Executive Board
John Chafos
CBRE

The Honorable Frank and Marcia Carlucci
Rose and Paul Carter
Casella Waste Systems, Inc.
CBRE

Celtgene

John Chafos
Corporate Executive Board
Covington & Burling LLP
Crane Fund for Widows and Children
The Crown Goodman Family
Dance Connection Parent Boosters
Paul Daversa
Deerfield High School 2012 School Chest
Rob Densen
Dentons
Diageo North America Foundation
Karen and Chris Donatelli
Jamie and David Dorros
The Dow Chemical Company

The Duchossois Family Foundation
E*TRADE
The Embassy of the United Arab Emirates
The Estée Lauder Companies
Every Breath Counts Foundation for Lung Cancer Awareness
Everything But Water
Jean-Marie and Raul Fernandez
Andrea and George Ferris
Lesly Findlay
Fitzpatrick, Celia, Harper & Scinto
Genentech
Goldberg Kohn
Greenberg Traurig LLP
Al Gruen
The Estate of Korbkarn Hanutsaha
Hematology-Oncology Associates of CNY, PC
Heritage Title Company of Austin, Inc.
Highmark Blue Cross
Blue Shield
Holliday Fenoglio Fowler, L.P.
Pamela Huttenberg and Brent Bergin
I.A. O’Shaughnessy Foundation
Lori Jagoda
Janice McArdle Cancer Research Foundation
Jones Day
Thomas Graham Kahn and Family
The Mary S. Kaiser Trust and the John P. Kaiser Family Trust
Kaye Scholer LLP
Kilpatrick Townsend & Stockton LLP
Estate and Trust of Julia Kunes
Sheila Labrecque
Dana and Michael Landow, Dulles Jet Center
Susan and David Landow, Dulles Jet Center
Levenfeld Pearlstein, LLC
Peta and Stephen Levin
Lilly Oncology
Karyn and Mitchell Liss
Littler Mendelson, P.C.
Lockton Companies, LLC
Maffucci Family Foundation
Mercurier Orchards
Miner Family Winery
Morphotek, Inc.
Morrison & Foerster LLP
Laurie and Bob Nakamoto
National Retail Federation
New York Land Services
Novartis Pharmaceuticals Corporation
Michelle and Chris Olson
The Media Trust
Pactolus Private Wealth Management
Suzy and Bob Pence
Perkins Coie LLP
The Peter Jay Sharp Foundation, Cynthia and Dan Lufkin
PhRMA
The Pleczynski Foundation
Quarles & Brady LLP
Quinn Gillespie & Associates LLC
Tim Rand and Cheri Chambers
The Randy Cappiello Foundation
David M. Rubenstein
The Safeway Foundation
Marian Renee Saltzberg Foundation
Second Sole
Rabekah and Ilan Shalit
Shook, Hardy & Bacon LLP
Sidley Austin LLP
Joseph S. Smith
Constance Mistlein
de La Haye St. Hilaire
Erie and Andrew Stern
Rachel and Alexander F. Stern
Paul G. Stern
Drs. John and Susan Stinson
Suzi Carmassi Cancer Foundation
Take Aim at Cancer Inc
The Thomas G. Labrecque Foundation
The Tom Zangas
Lung Cancer Foundation
TTR Sotheby’s International Realty
University of Kansas Hospital
Upstage Lung Cancer
Vanderbilt-Ingram Cancer Center
Walgreens Co.
Waterton Residential
WBL Services
Wells Fargo Multifamily Capital
Whirlpool Corporation
Ambassador C. Howard Wilkins and Mrs. Wilkins

Individual, Corporate and Organizational Gifts of $250 - $4999
Holly C. and Larry Aaronson
Isabella Abbassi
Nicolet and Aaron T. Abelson
Jeffrey Abish
ABM Office Solutions, Inc.
Kenneth Abrams
Marilyn and Richard E. Abrams
Abramson Cancer Center of the University of Pennsylvania
Mario Aburacah
Accelerated Rehabilitation Center
Cheryl Adair
Kathleen Addazio
Scott and Monica Addington
Sydney Addis
Adèle’s Kitchen
Sasha Adler
Marie Adler-Kravecas
AddCare Systems
Advanced Imaging Partners, Inc.

Advanced Medical Technology Association (AdvaMed)
Debbie Aghion
Kimberly Agnew-Heard
Karen Agrest
Dan Agrokin
Caroline Aguilar
Anthony Aguliera
Albany Hardware, Inc.
Alexine Clement Jackson and Aaron G. Jackson Charitable Fund
Carolyn Allen
Frances and James Allen
The Allstate Foundation
Dick Almy
American Cancer Fund
American Family Insurance
American Radiology Services, LLC
Amica Insurance
AML Residential
Becky Anderson
Chunakah Anderson
Noreen and Steve Anderson
Sandra and Joe Anderson
Tony Anderson
Michelle Andreoli
Kristy Andrews
Bernie Anger
Tracy and Howard Ankin
The Annette M. and Theodore N. Lerner Family Foundation
Susanna Ansala
Melissa Apel and Tony Modelfino
Jonathan D. Appelbaum
Applebee’s
Louis Arbetter
Diane and Thomas Arenberg
Shanthi Arbindi
Said Armutcuoglu
Natercia Arn
Sheila Arnold
Shari and Jeff Aronson
Allyson Arredondo
Asbestos.com
Connie Aslaksen
Assurant Foundation

* LUNGevity appreciates every contribution, and we have made a concerted effort to accurately list all donors of significant contributions in fiscal year 2013. If your name is misspelled or missing from this report, please accept our apology and call Carol Perline at 240-454-3100 x112 with the correct information.
Special thanks to our grassroots event coordinators — those dedicated individuals who donated their time to lead our many events around the country!

Isabella Abbassi
Monica Addington
Scott Addington
Rachael Agee
Allyson Arredondo
Aisha Avery
Katie Avesian
Jasmine Banks
Jennifer Barnhart
Justin Behm
Jennifer Atterbury
Aubrey French
Rafaela Garcia
Sue Atwell
Frankie Carlin
Stuart Bernstein and
Debbie Chase
Sue Bersh
Dennis Ault
Maryellen Basile
Karen Auerbach
Maryellen Basile
Amy and Bret Baier
Melinda Baglio
Melissa Mercier Lillard
Melissa Barkin
Tiffany Bianco
Sandra Bermudez
Ellen Bermel
Frank Bernhardt
Stuart Bernstein and
Mrs. Bernstein
Suzanne and William
Bettman
Christine Bezmalinovic
Tiffany Bianco
Randall Bieber
Big Fan Tailgating
BIND Biosciences
Al Bingenheimer
Birmingham Investments LLC
Beth and Gary Birnbaum
Dr. Richard and Dee
Bittman
Sheri and Robert Blacher
Blackstone Consulting LLC
Bertram Blaisdell
Elizabeth Kaufman Blalack
Michael Bliss
Blitt and Gaines PC
Alan Block
J Block
Bloom Organization
The Bloomingdale's Fund
of the Macy's Foundation
Bloomingdale's, Inc.
Blue Chip Marketing
Worldwide
Blue Cross Blue Shield
of Kansas City
Blue Cross of Northeastern
Pennsylvania
Blue Ridge Coin Laundry
Blue Valley School District
Blue Waters Foundation
Desiree and Barry
Blumenthal
Julia and Grant Blumenthal
Nancy and Lawrence Bluth
BNSF Railway Company
Robert A. Boaman
Cynthia Bock
David Bode
The Boeing Company
Francis Boggan
Scott Boggins
Paul Bohmbach
The Bon Ton Stores, Inc.
David Bondy
Matthew Bonilla
Gina Bono
Dr. Philip and Judith Bonomi
Andrew Booth
Brad Borbridge
John Bosacco
Boston Properties
Olivia Boswell
Stephen Bowen
Michele and Tom Bowles
Bowman & Company, LLP
A. Price Boxley
BP Foundation, Inc.
Bradley Associates
Bradley Charitable Fund
Howie Braithwaite
Robert Bralower

Isabella Abbassi
Monica Addington
Scott Addington
Rachael Agee
Allyson Arredondo
Aisha Avery
Katie Avesian
Jasmine Banks
Jennifer Barnhart
Justin Behm
Jennifer Atterbury
Aubrey French
Rafaela Garcia
Sue Atwell
Frankie Carlin
Sandra Bermudez
Ellen Bermel
Frank Bernhardt
Stuart Bernstein and
Mrs. Bernstein
Suzanne and William
Bettman
Christine Bezmalinovic
Tiffany Bianco
Randall Bieber
Big Fan Tailgating
BIND Biosciences
Al Bingenheimer
Birmingham Investments LLC
Beth and Gary Birnbaum
Dr. Richard and Dee
Bittman
Sheri and Robert Blacher
Blackstone Consulting LLC
Bertram Blaisdell
Elizabeth Kaufman Blalack
Michael Bliss
Blitt and Gaines PC
Alan Block
J Block
Bloom Organization
The Bloomingdale's Fund
of the Macy's Foundation
Bloomingdale's, Inc.
Blue Chip Marketing
Worldwide
Blue Cross Blue Shield
of Kansas City
Blue Cross of Northeastern
Pennsylvania
Blue Ridge Coin Laundry
Blue Valley School District
Blue Waters Foundation
Desiree and Barry
Blumenthal
Julia and Grant Blumenthal
Nancy and Lawrence Bluth
BNSF Railway Company
Robert A. Boaman
Cynthia Bock
David Bode
The Boeing Company
Francis Boggan
Scott Boggins
Paul Bohmbach
The Bon Ton Stores, Inc.
David Bondy
Matthew Bonilla
Gina Bono
Dr. Philip and Judith Bonomi
Andrew Booth
Brad Borbridge
John Bosacco
Boston Properties
Olivia Boswell
Stephen Bowen
Michele and Tom Bowles
Bowman & Company, LLP
A. Price Boxley
BP Foundation, Inc.
Bradley Associates
Bradley Charitable Fund
Howie Braithwaite
Robert Bralower

2013 Annual Report
LUNGevity Foundation
19
Branch Banking and Trust Company
The Brandsma Family Foundation
Doreen R. Braniff
Heidi Brarenwalsh
Ryan Braun
Arthur Braverman
Alisa Brenes
Lori Brennan
Barbara and Butch Briggs
Adam Brink
Brio Tuscan Grill
Trenton Brisby
Raymond J. Briscoe
Randall Broad
The Honorable William Brock and Mrs. Sandy Brock
Shannon and James Broderick
Carolina Broderick
Alex T. Brodowski
Robert Brody
Ina Broeman
Brooklyn College Central Depository
Student Organizations
John Brooks
Vicki Brody
Derek Brown
Diane and Leonard Brown
Katie Brown
Marisa Brown
Brown-Forman Corporation
Collette and Anthony Bruce
Patrick Bruno
Robert Bruno
Nancy T. Bubes
Annabelle Buckner-Allen
Rosemary Buddendorf
Karen Buer
Buffalo Wild Wings
Kevin Buffum
Russell Bundschuh
Anthony Buoscio
Laine Burdett
Beth Burke
Robert Burke
Brian Burlace
Robert Burrink
Heather Busicchia
Gayle and Paul Byck
Robert Byrne
Chris Byrnes
C.R. Wings
Morise and Jack Cabasso
Robert Caffrey
Carol Caggianocuevas
Eugene Callen
The Cancer Institute at St. Joseph Medical Center
Douglas Canfield
Gwen Canfield
Dr. and Mrs. Chris Cannova
Kara Capasso
Christopher Caperton
Salvatore Capizzi
Luigi Capolino
Amelia Caporale
Staci and Tony Capuano
Stephen Cardone
Mark Carhart
Mark Carlinsky
Jean and Joseph Carnese
Mark Carnow
Katie and Steve Carpenter
Samuel Carpenter
Barbara J. Carr
Megan Carrick
Elizabeth Carroll
Jimmy Carroll
Michael Carson
Matthew Casamassima
George Casey
Rachel Cashwell
Cassidy Turley Midwest, Inc.
Marilyn Castagno
Carlos Castano
Jennifer Castano
Shelby Cavanaugh
Allen Cavedo
Anthony Cawthorne
Chris Cazier
Kristin and John Cecchi
Centerview Partners
Richard Chadwick
Adam Chakian
Maureen and Scott Chakian
Vivian Chamberlain
Ashi Chan
Geovanna Chan
Scott Chan
Bonnie Chandler
Maura Chapey
Javier Chapochnick
The Charles A. and Betty Bott Cancer Center
Julie Chase
Staci and Corey Chase
Joann and Gerald Chasen
Cooper Chastain
Sandra and Robert Chatz
Ui-Wing Cheah
Dr. Martin A. Cheever
The CHEST Foundation
Bradley Chestler
Ronald L. Chez
Debbie and David Chizewer
Chopra Cilento Pietroforte
Kiely
Chris Gemmill Memorial
Open
Bill Chrisman
Margie Christian
Shirin Christoffersen
Edward Chu
Norma Chu
Harry Chung
Betsy Ciarcia
Lauren Ciccarone
James Cimador
Brian Cizek
CJE SeniorLife/Weinberg Community
Leticia Clark
Stuart Clark
Terese Clark
Michael Clayman
Suzette J. Clayton
Robert Cleiss
Jeanne Cleveland
CLG Employer Resources
Beth Cline
Marianne Cline
Lori Cloch
Sylvia and Thomas Close
Club Inhale/Exhale, LLC
CMC Group Community Foundation
CNA Foundation
COA LLC
Coach
Carolyn Coan
Erick Coan
Caren Cohen
Caryn and Steven Cohen
Deborah and Joel Cohen
Joseph Cohen
Linda F. Cohen
Lisa Cohen
Marcy and Mitchell Cohen
Margot Cohen
Roberta Cohen
Rose and Robert L. Cohen
Roseanne Cohen
Chris Colapietro
Adam Cole
Janis Colella
Maureen and Tim Coleman
Megan Coleman
Joseph Colletti
Brian Collie
Jennifer Collins
Robert Collins
Jeanne Colquette
Columbia Medical Practice
Community America
Edward Conlon
James Connelly
Gerald Connors
Conquer Cancer Coalition
Continuum Dynamics
Daniel Conway
Gordon Cook
Joe Cook
Margaret Cooke
Merle Cooper and Dan Roumbos
Melissa and David Copeland
Laurie Cortesi
Richard Cortesi
Annamarie Coughlin
Michael Coughlin
Country Club Bank
Linda Courie
Paul Coviel
Covidien
Cozen O’Connor Foundation
Cheryl Cramblit
David H. Crandall
Harriet F. Crane
Susan Crank
Lauren and David Cranston
John Crawford
Eunice Creamer
Creative, Inc
Sharon and Kevin Crippen
Susan and Ed Croft
Scott Cromwell
Marni and Don Cronk
Crowley Associates
Realty, Inc.
Tammy and William Crown
CSL Behring
Robert Cuddeback
Kathy Cuddy
Susan Culbert
Cathy Cullen
Mollianne Cunniff
Amy Curley
Joseph Curro
Timothy Curry
Annie Curtin
Donna Cuti
Sarah Cypotte
Cyril F. and Marie O’Neil Foundation
Walter Czamecki
D&G Trucking Company
Dr. Dondi Dahlgaard and Mark Schoenfeld
Dalla Riva
Doris Dallow and Stephen Nechtow
Kelvin Dally
Virginia Dam
Louis D’Amato
Jim Dandy
Twila and Thomas Daniels
John Danner
Lori Dar
Linda Bauer Darr
Madeleine Dassule
Asnat Davidi
Laura Davidson
Adrienne Davis
Jessica Davis
Charles Dawson
The Honorable Mimi Dawson and The Honorable Rhett Dawson
DB Cooper
Renzo De Mec
Giorgio De Santis
Deborah Heart and Lung Center
Karen Decarlo
Dennis Decker
Dedicated Imaging
The Defeo Law Firm, LLC
Delaney Family Foundation Fund
Delco Road Runners Club
Betsy and William Delphos
Basia and Joseph DeMali
Alice Dembner
Demdaco
Timothy Demery
Dempsey’s Brew Pub & Restaurant
Douglas DeNatale
Dendreon
Claude Denker
Elaine Denney
Holly Depatie
Howard Derdiger
David Dermer
Matthew Deschamps
Stephen Desesa
Alan Destrabits
Detroit Country Day School
Toby and Neal Deutsch
Deutsche Bank Americas Foundation
Barbara Deving
John Devoy
Carol Di Giacomo
Phyllis Diamond
Sid Diamond
Jeff DiBartolomeo
Robert Dickerson
Gina DiDomenics
Sean Dietrick
Vito Difino
Elinor Dilorio
Pamela Dill
Kris Dimlich
Leonard DiPasqua
Carol DiRaimo
Distilled Spirits Council
Jessica Dixon
Matthew Dizigan
DMX Music
Arlene and Ira Dobren
Amanda Doherty
Great Moments, Inc.
Lou Green
Richard Green
Sheryl Green and
Marcus Newman
Jocelyn and Tim Greenan
Heather and Michael
Greenbaum
Jeri Greenberg
The Greene Turtle
Janet Greene
Lisa and Neil Greene
Peggy Greene
Josh Greenhill
Greenwood Inn Lung
Cancer Concert
Katherine and Kenneth
Greisman
Devora Greco
Geoffrey Grieve
Grifols
JT Groarke
David Grosky
Julie and Stefan Gross
Michael Gross
Joan E. Grossman
David Grove
Georgina Grove
Gary Gruen
Karen Gruen
Susan Guenzel
Craig Guice
Sheila Gursky
Dan Guyder
Steven Guzinski
Gymnastics Learning Center
Hachler Investments, LLC
Nicole and Philip Hadley
Mary and Robert Haft
Hagerstown GT, LLC
Ashley Hahn
Tom Hahn
Scott Haig
Anthony Halas
Sam Halkias
Caroline Hall
Garrett Hall
Meredith Hall
Ralene and Matt Hall
Susan Haller
Brenton Hamdorf
Jeffrey Hamilton
Loretta Hamilton and
Jack Cohen
Kevin Hammond
Ron Hamu
Dr. Samir Hanash
The Honorable and
Mrs. Lloyd Hand
Jeffrey L. Handwerker
Kathy Hanes
John Hannah
Anne Harder
Hardman Distribution
Corporation
Harley Marine Services
Elisa and John Harmon
Alan Harris
Bonnie and Michael Harris
Erica and Paul Harris
Sharon Harris
William Harrison
Clarke Hart
John Hartner
Neva and Thane Hascall
Brandon Hastings
Janna Hawkins
Greg Hawthorne
Brian Hay
Jim Hayden
Charles Haynes
Tanya Head
Nancy Heath
Joseph Heatherly
Steve Heay
Janelle and Mark Hegarty
Hedy Helfand and
Patrick Kelly
Patti and Steve Helfand
Hematology-Oncology
Associates of CNY
Dianne and Richard
Hendricks
Alicia and Brian Henneberry
Jean Henry
Ricki and George Henschel
Herb Gillen Agency
Barbara Herer
Marlyn M. Hering
Heritage Bank of Commerce
Paula Hermanny
Heather Hermiz
Cathaleen Hernandez
Sheila Herrig
Amy Herzog
Louanna Heuhsen
Matthew Heyman
Gregory Hickey
Mary and Kenneth Higgins
Highwoods Properties, Inc.
Scott Hilkene
David Hill
Parker Hill
Michelle and David Himer
Michelle and Steven Hirsch
Laura Hirshon
Roland Hiawaty
Laurie and Andrew
Hochberg
Sara Hochman
Margaret Hodge
Beth and Kevin Hoffman
Lisa and Perry Hoffman
Virginia A. Hogan
Heather Hollaway-Wilson
Holman Automotive
Group, Inc.
Danielle Holmes
Jeanne Hilt
Holy Trinity Catholic School
HomeStar Bank Employees
Homestead Funding Corp.
Taylor Hood
Margaret Horn
Kathleen Hotell
Howard and Jacqueline
Chertok Foundation
Barclay Howard
HP YourCause, LLC
Jenny Huang
Lauren Hudson
Edward G. Huebner—
RE/MAX Allegiance
Maria Huff
Hughes Hubbard & Reed LLP
J. C. Hughes
Humes Funeral Home
Lauren Humphries
Hunt Valley GT LLC
Diane Hunt
Laura Hunt
Hunter Douglas
HVC Associates
Edward Hyland
Jean Hynes
I.A.M.A.W. Local 1280
Bill Iannaci
Il Forno Pizza
Illinois Cancer Specialists
Indian Prairie Community
School District
Indy Custom Cornhole, LLC
Infinity Pharmaceuticals, Inc.
ING Financial Partners
in Bellevue
Interactive Data Corporation
Interline Brands
International Franchise
Association
Involve, LLC
Isle Casino Racing
Pompano Park
David Israel
Marta Istomin
Michele Ivanski
JAB Produce, Inc.
Melissa Jackson
Jacksonville Chrysler Dodge
Elaine Jacobs
Frieda P. Jacobs and
Frederic R. Klein
Jaffe, Raitt, Heuer & Weiss
Cheri and Milton Jaffe
Earl Jaffe
Saundra and Thomas James
Stacey James
Julia Jankord
Jazzy Auto Imaging
JDL Technologies, Inc.
Jewelry Night Out
Dolly Jhonsa
JLL Partners
John & Jacqueline Sigler
Trust Fund
Johns Hopkins Medicine
Johnson & Johnson
Donna J. Johnson
Elissa Johnson
Tammy Johnson
Sarah Johnston
Ursula and Alan Jonas
Jones Lang LaSalle
Ava Jones
Barbara and Bob Jones
Emily and Bob Jones
Heather Jones
Melody Jones
William Jones
Bradley Jordan
Jose Marti Freshman
Academy
Adam Joseph
Eric Josephs
Geraldine and J. Michael
Joyce
Mary Holland Joyner
JP Morgan Chase
Kerry Kafer
Douglas Kahn
Joshua Kahn
Daniel Kahrs
Albert Kaiser
Barbara and Joseph Kampf
Jennifer Kane
Joy and Irwin Kane
Christina and Dimitri
Kapetan
Doris Kaplan
Harry Kaplan
Leonard Kaplan
Kappa Sigma Epsilon
Tina and Larry Karchmar
David Karp
Sandra Karr
Sandra and Steve Karson
Andrea Kasarsky
Michael Kasdin
Jackie Kassam
Katten, Muchin,
Rosenman LLP
Steven Katz
Sarah Katz Liebowitz
Peter Kay
The Kaye Family Foundation
Juliet Keane
Christopher Keating
Sherry Keating
Keck’s Agency, Inc
Vicki Keedy
Stephen Keefe
Michael Keegan
Diane Kehl
Nancy Keil-Cubertson
Keith Construction Inc.
Gail Keller
Peter Kellner
Cynthia H. and James L.
Kemper
Victoria Kendall
William Kendrick
Edward Kennedy
Jennifer Kennedy
Patrick Kennedy
Patrick Kenney
Laura Kennington
Peter Kenny
Edward Keogh
Robert Keogh
John D. Kernan, DMD, PA
Kevin’s Place
Omar S. Khalil
Giovanna Kiams
Susie Kim
Kimberly Clark Foundation
Laura Kinder
The King Family
Ann and Patrick E. King
Kingsway Logistics
Richard Kinsley
Patricia Kirkland
Lyric Kite
Kiwanis Club of
Charlottesville
Renee and Wayne Klett
Ann Klawitter
Merle Klebanoff
Lisa and Steven Kleiman
Amy and David Klein
James Klein
Sheila Klein
Rick Klepp
James Kneisel
John Kneisel
Kristy Knight
Robert Knighton
Amy and Brandon Koenig
Julie Kogan
Beth Kohl
Rachel Kohler and
Mark Hoplamazian
Kohl’s
John Konther
Dan Korman
Debra Korman
Naomi and Jack Korol
Overall Financial Health The financial activities of LUNGevity Foundation were audited by Ostrow Reisin Berk & Abrams, Ltd. For our complete audited financial statements, please visit our website at www.LUNGevity.org.

LUNGevity Foundation remained fiscally strong in FY2013, thanks to a diverse set of donors. We were able to continue to grow our research and education programs, while adding support resources and increasing the population we serve.

Funding Sources
- EVENT REVENUE: 46%
- INDIVIDUAL DONATIONS: 26%
- CORPORATE GIVING: 14%
- FOUNDATION GRANTS: 14%

Program Expenses
- RESEARCH: 75%
- SUPPORT: 15%
- PATIENT AND PUBLIC EDUCATION: 10%

I was diagnosed with early stage lung cancer by chance. Because of chest pain on my right side, I went to the ER. I was concerned about my heart, because heart disease runs in my family. I never found out what was causing my chest pains that day, but I did find out that I had a mass on my left lung. Until then, I never knew people could get lung cancer if they didn’t smoke. I just feel so very fortunate that my cancer was accidentally detected early and I was able to be “cured.” I want everyone else to have the opportunity for early detection.

JAN GIBSON
Diagnosed in 2005 with Stage 1A non-small cell lung cancer
# STATEMENT OF FINANCIAL POSITION

*June 30, 2013*

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$3,104,843</td>
<td>$4,070,951</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>201,731</td>
<td>109,556</td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>638,302</td>
<td>589,669</td>
</tr>
<tr>
<td>Pledges receivable</td>
<td>671,398</td>
<td>646,534</td>
</tr>
<tr>
<td>Security deposits</td>
<td>9,722</td>
<td>20,986</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>34,898</td>
<td>28,391</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$4,660,894</td>
<td>$5,466,087</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$31,660</td>
<td>31,113</td>
</tr>
<tr>
<td>Accrued payroll and vacation liabilities</td>
<td>91,702</td>
<td>26,985</td>
</tr>
<tr>
<td>Grants payable</td>
<td>1,507,206</td>
<td>2,500,000</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>19,230</td>
<td>17,353</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>1,649,798</td>
<td>2,575,451</td>
</tr>
<tr>
<td>Net assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>2,339,698</td>
<td>2,239,102</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>671,398</td>
<td>651,534</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>3,011,096</td>
<td>2,890,636</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$4,660,894</td>
<td>$5,466,087</td>
</tr>
</tbody>
</table>

*Note: In 2013 the Board of Directors approved additional spending for Program Services in order to reduce the amount of cash held in reserve accounts.*
How to get involved  We would not be where we are today without the generous support of people like you. Through your involvement, you have helped LUNGevity continue to grow and fund high-quality lung cancer research, while providing vital support and education services.

There are numerous ways to get involved and support LUNGevity throughout the year.

• **Donate to help us stop lung cancer.**

• **Host a Breathe Deep community-based event.** Breathe Deep events are a great way to get people involved and spread awareness about our cause.

• **Sign up for our electronic newsletter.** Once a quarter, you will receive LUNGevity’s latest news updates, information on upcoming events and other relevant information. Visit LUNGevity.org to subscribe.

• **Become a Sustaining Donor.** Set up an automatic monthly donation. This ongoing commitment to stopping lung cancer can make a real difference.

• **Join the Lung Cancer Support Community’s online support network.** Connect with others who have been affected by lung cancer to get and give support.

• **Become a LifeLine Support Partner.** Volunteer to mentor and offer encouragement, advice, experience, and hope to those newly diagnosed or their caregivers through a one-on-one personal connection by email or telephone.

• **Sign up for LUNGevity LinkUP.** Join us in our efforts to educate and advocate for increased research funding and better resources for lung cancer patients/survivors and their loved ones.

Connect with us!

• **Watch and share videos on YouTube.** LUNGevity’s YouTube channel allows you to see lung cancer survivors telling their own stories, moving event highlights, PSAs, and more.

• **Become a fan of our Facebook page.** We post photos of events, articles about LUNGevity and more! “Like” our Facebook page and share it with others.

• **Follow us on Twitter.** Get up-to-date news on LUNGevity and our partnerships, events and latest happenings, and retweet to spread the word.

• **Indulge in everyone’s guilty pastime: Pinterest.** With inspirational quotes; survivor and event photos; and pinnings of our favorite partners, products and services for people affected by cancer, LUNGevity’s Pinterest page is a fun way to connect.

I think it is really important to raise awareness about lung cancer and get rid of the stigma that it is only a smokers’ disease. It is everyone’s disease. I am just one of many examples of a non-smoker who has been diagnosed with lung cancer.

LOIS GREEN  
Marathon Runner  
Diagnosed in 2006 with stage I NSCLC
BOARD OF DIRECTORS

Peter Babej
Global Co-Head of the Financial Institutions Group
Citigroup, Inc.

Grace Bender
Owner
Infinisity, Inc.

Susan Bersh, Secretary
Vice President-Communications
AMLI Residential

Andrea Ferris
Chairman and President
LUNGevity Foundation

Pierre Massion, MD
Chairman
LUNGevity Scientific Advisory Board
Professor of Medicine
Ingram Professor of Cancer Research
Professor of Cancer Biology
Director, Thoracic Program at the Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center

Chris Olivier
Principal
Craft Catalyst

Jerome Sorkin, Vice Chairman
Executive Director
Corporate Executive Board

Alexander F. Stern
Chief Operating Officer
Lazard

Andrew Stern
Founder and Managing Partner
Aurify Brands

Paul G. Stern
Former Presiding Director
The Dow Chemical Company
Former Director
Whirlpool Corporation

Jason Swanson, Treasurer
Director
Harris NA/BMO Capital Markets

Marc Swerdlow
President and General Counsel
Waterton Associates LLC

HONORARY LEADERSHIP BOARD

Reto Braun
Chairman
Earth Council eLearning

Nancy G. Brinker
Founder and Chair, Global Strategy
Susan G. Komen for the Cure

Jeff M. Fettig
Chairman and Chief Executive Officer
Whirlpool Corporation

Vernon E. Jordan, Jr.
Senior Managing Director
Lazard

Andrew N. Liveris
President, Chairman and Chief Executive Officer
The Dow Chemical Company